^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Gastroesophageal Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy
Published date:
03/30/2021
Excerpt:
...patients with TP53 mutations had worse OS from ICIs compared to TP53-wildtype patients in the MSS subgroup (5 vs. 21 months, HR=2.39, 95%CI: 1.24-4.61, p=0.016).
DOI:
10.1016/j.annonc.2021.03.203
